Development of highly stable and de-immunized versions of recombinant alpha interferon: Promising candidates for the treatment of chronic and emerging viral diseases

Human interferon alpha (hIFN-α) administration constitutes the current FDA approved therapy for chronic Hepatitis B and C virus infections. Additionally, hIFN-α treatment efficacy was recently demonstrated in patients with COVID-19. Thus, hIFN-α constitutes a therapeutic alternative for those countr...

Descripción completa

Detalles Bibliográficos
Autores principales: Giorgetti, Sofía Inés, Etcheverrigaray, Marina, Terry, Frances, Martin, William, De Groot, Anne Searls, Ceaglio, Natalia, Oggero, Marcos, Mufarrege, Eduardo Federico
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Inc. 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8595249/
https://www.ncbi.nlm.nih.gov/pubmed/34798238
http://dx.doi.org/10.1016/j.clim.2021.108888

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8595249/
https://www.ncbi.nlm.nih.gov/pubmed/34798238
http://dx.doi.org/10.1016/j.clim.2021.108888

Ejemplares similares